EP 3712139 A1 20200923 - ANTI-HBV TETRAHYDROISOXAZOLO[4,3-C]PYRIDINE COMPOUNDS
Title (en)
ANTI-HBV TETRAHYDROISOXAZOLO[4,3-C]PYRIDINE COMPOUNDS
Title (de)
ANTIHBV TETRAHYDROISOXAZOLO[4,3-C]PYRIDINVERBINDUNGEN
Title (fr)
COMPOSÉS DE TÉTRAHYDROISOXAZOLO[4,3-C]PYRIDINE ANTI-VHB
Publication
Application
Priority
- CN 201711138922 A 20171116
- CN 201810339723 A 20180416
- CN 2018115857 W 20181116
Abstract (en)
Disclosed are a class of anti-HBV tetrahydroisoxazolo[4,3-c]pyridine compounds and pharmaceutically acceptable salts thereof or isomers thereof, the compounds being represented by the formula (I).
IPC 8 full level
C07D 261/00 (2006.01); A61K 31/424 (2006.01); A61K 31/4355 (2006.01); A61K 31/437 (2006.01); A61P 31/12 (2006.01); C07D 413/12 (2006.01); C07D 413/14 (2006.01); C07D 498/04 (2006.01)
CPC (source: EP US)
A61K 31/424 (2013.01 - EP); A61K 31/4355 (2013.01 - EP); A61K 31/437 (2013.01 - EP); A61P 31/12 (2017.12 - EP); A61P 31/20 (2017.12 - US); C07D 498/04 (2013.01 - EP US)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
EP 3712139 A1 20200923; EP 3712139 A4 20210505; CN 111247131 A 20200605; CN 111247131 B 20220218; JP 2021503466 A 20210212; JP 7250015 B2 20230331; PH 12020550649 A1 20210426; SG 11202004594S A 20200629; US 11572372 B2 20230207; US 2020377517 A1 20201203; WO 2019096241 A1 20190523
DOCDB simple family (application)
EP 18879872 A 20181116; CN 2018115857 W 20181116; CN 201880070173 A 20181116; JP 2020526967 A 20181116; PH 12020550649 A 20200517; SG 11202004594S A 20181116; US 201816764129 A 20181116